Evidence map›Paper›PMID 34791506›Full record

ArticleMolecular medicine reports2022

CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.

Linjin Li, Yiren Hu, Dake Chen, Jianlong Zhu, Wenshuo Bao, Xiaomin Xu, Heyi Chen, Wu Chen, Rui Feng

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. CMTM4 inhibits gastric tumorigenesis and metastasis.Journal of gastrointestinal oncology · 2024
    Article
  6. Review
  7. Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Linjin Li *Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Yiren Hu *Department of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Dake ChenDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Jianlong ZhuDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Wenshuo BaoDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Xiaomin XuDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Heyi ChenDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Wu ChenDepartment of Urology, The Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, Zhejiang 325000, P.R. China.
Rui FengDepartment of Urology, Zhenjiang Hospital of Chinese Traditional and Western Medicine, Zhenjiang, Jiangsu 212002, P.R. China.
Wenzhou Medical University · CNIntegrated Chinese Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) endangers the life and health of older men. Most PCa cases develop into castration‑resistant PCa (CRPC) within 2 years. At present, the molecular mechanisms of the occurrence and development of PCa and its transformation to CRPC remain unknown. The present study aimed to investigate the role of CKLF‑like Marvel transmembrane domain containing family member 5 (CMTM5) in PCa and its molecular mechanism

Indexed as

AgedAged, 80 and overApoptosisCell Line, TumorCell MovementCell ProliferationChemokinesDown-RegulationErbB ReceptorsGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMARVEL Domain-Containing ProteinsMiddle AgedPhosphatidylinositol 3-KinasesChemokinesCMTM5 protein, humanEGFR protein, humanErbB ReceptorsMARVEL Domain-Containing ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor ProteinsCKLF‑like Marvel transmembrane domain containing family member 5EGFRepithelial‑mesenchymal transitionPI3K/AKT signaling pathwayprostate cancer

Identifiers

PMID34791506
PMCPMC8628290
OpenAlexW3211804865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.